Silo Pharma Business Summary

Silo Pharma, Inc. (SILO) is a developmental-stage biopharmaceutical company that operates a dual-pronged business model focused on central nervous system (CNS) therapeutics and a diversified digital asset treasury. The company generates revenue primarily through the licensing of its intellectual property and technology rights to third-party pharmaceutical firms, supplemented by potential milestone and royalty payments. Its biopharmaceutical segment specializes in merging traditional drug delivery systems—such as intranasal and topical formulations—with psychedelic research to treat conditions like PTSD, fibromyalgia, and Alzheimer’s disease. In August 2025, Silo expanded its operations by launching a cryptocurrency treasury platform that generates value through staking yields and active portfolio management of assets like Bitcoin and Solana. Within the competitive landscape, Silo competes with psychedelic-focused biotech firms such as COMPASS Pathways, MindMed, and Beckley Psytech, as well as CNS specialists like Ovid Therapeutics. Silo distinguishes itself as a micro-cap player utilizing a lean, capital-efficient model that bridges high-science drug development with decentralized finance (DeFi) treasury strategies. The company is led by Founder and CEO Eric Weisblum, a veteran investor with over 20 years of experience in structuring financial instruments and in-licensing therapeutic assets. The scientific and technical direction is overseen by Dr. James (Jim) Kuo, Vice President of R&D, who holds an MD from the University of Pennsylvania and an MBA from Wharton; Dr. Kuo’s pedigree includes executive roles at Pfizer and leadership positions at several clinical-stage biotechs. Financial operations are managed by CFO Daniel E. Ryweck, a CPA with extensive experience in SEC compliance and financial reporting for public ventures. The company’s strategic oversight is supported by a board of directors that includes Dr. Kevin Muñoz and Wayne D. Linsley, alongside a specialized Crypto Advisory Board chaired by Corwin Yu. Notable institutional backing has historically included positions from Anson Funds Management LP, AdvisorShares Investments LLC, and Renaissance Technologies LLC, reflecting a mix of biotech and quantitative investment interest.